CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Filana Therapeutics Expects Screening for Phase 2a Simufilam Epilepsy Trial to Begin by Q1 2027

By Public Technologies
  • Filana Therapeutics announced published preclinical simufilam findings as it prepares a Phase 2a trial in tuberous sclerosis complex-related epilepsy.
  • Patient screening for the planned trial is expected to begin by the first quarter of 2027.
  • Results published in Cells showed reduced cellular stress responses and restored mitochondrial function in engineered human cells.
  • The findings suggest a mechanism distinct from direct mTOR inhibition; clinical studies are needed to establish seizure benefits in patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854802) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk